Xeris Biopharma (XERS) Stock: Buy, Sell, or Hold?
XERS - Xeris Biopharma Holdings, Inc. Common Stock
$9.08
-0.17 (-1.84%)
âŧ
5d:
-0.22%
30d:
+5.83%
90d:
+8.48%
WAIT
LOW Confidence
Analysis Updated: Oct 2, 2026 12:00 AM ET
Earnings: Nov 05, 2026
Get Alerted When XERS Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: XERS is fairly priced but lacks strong directional signals. At 6.0% expected growth, valuation appears stretched. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: XERS is fairly priced but lacks strong directional signals. At 6.0% expected growth, valuation appears stretched. Wait for clearer setup or better entry on dips.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$10.71
Based on 7.0% avg growth
INTRINSIC VALUE TODAY
$6.65
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 19.6x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: XERS is currently trading at $9.08, which is considered slightly high relative to its 30-day fair value range of $7.92 to $9.20. From a valuation perspective, the stock is trading at a premium (Forward PE: 23.3) compared to its historical average (19.6). At these levels, the market is pricing in 6.0% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, XERS is in a strong uptrend. Immediate support is located at $8.16, while resistance sits at $11.33.
Market Sentiment: XERS scores 8/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $12.29 (+35.3%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, XERS is in a strong uptrend. Immediate support is located at $8.16, while resistance sits at $11.33.
Market Sentiment: XERS scores 8/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $12.29 (+35.3%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
SLIGHTLY HIGH
Historical Trading Range
$7.92 -
$9.20
Company Quality Score
43/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
41.9%
All Signals
- BEARISH: Weak technical setup (8/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 35.3% below Wall St target ($12.29)
- NEUTRAL: Trading at premium valuation - market expects 6.0% growth which is achievable
- WARNING: Composite score 43/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$7.92 -
$9.20
Current vs Trading Range
SLIGHTLY HIGH
Support & Resistance Levels
Support Level
$8.16
Resistance Level
$11.33
Current Trend
Strong Uptrend
Technical data as of
Oct 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
23.28
Wall Street Target
$12.29
(+35.3%)
Revenue Growth (YoY)
28.7%
Profit Margin
-5.1%
Valuation Premium vs History
+6.0% premium
PE vs Historical
23.3 vs 19.6
STRETCHED
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+6.0%
(market-implied from PE analysis)
1-Year Target
$9.62
(+6%)
2-Year Target
$10.20
(+12%)
3-Year Target
$10.81
(+19%)
3-Yr Target (if PE normalizes)
(PE: 23â20)
PE COMPRESSION
$9.10
(+0%)
Earnings growth offset by PE compression
Share & Embed Analysis
Last updated: October 03, 2026 8:46 PM ET
Data refreshes hourly during market hours. Next update: 9:46 PM
Data refreshes hourly during market hours. Next update: 9:46 PM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is XERS showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences IâĻ |
STRONG BUY
25 analysts |
$208 | 62 BUY |
|
ZTS
Zoetis Inc |
BUY
20 analysts |
$96 | 58 HOLD |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$108 | 56 HOLD |
|
AQST
Aquestive Therapeutics IâĻ |
STRONG BUY
9 analysts |
$9 | 67 BUY |
|
BCRX
BioCryst PharmaceuticalsâĻ |
STRONG BUY
12 analysts |
$21 | 47 HOLD |